Valuation: Therapeutic Solutions International, Inc.

Market Cap 1.14M 1.02M 948K 863K 1.63M 110M 1.64M 11.46M 4.46M 56.09M 4.28M 4.19M 180M P/E 2022
-4.13x
P/E 2023 -1.46x
Enterprise Value 2M 1.79M 1.66M 1.51M 2.85M 193M 2.87M 20.1M 7.82M 98.37M 7.51M 7.35M 316M EV / Sales 2022
81.1x
EV / Sales 2023 47.1x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
24-11-20 Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-08-19 Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-05-30 Therapeutic Solutions International, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24-04-17 Therapeutic Solutions International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
24-04-16 Therapeutic Solutions International, Inc. Auditor Raises 'Going Concern' Doubt CI
24-03-04 Therapeutic Solutions International Receives Patent on Commercially Available QuadraMune Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients CI
23-12-11 Therapeutic Solutions International, Inc. Announces Formation of ALS Biologics Inc to Commercialize Regenerative Technologies Related to Dreaded Motor Neuron Disease CI
23-11-14 Therapeutic Solutions International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-10-20 Therapeutic Solutions International, Inc. Announces Successful First Treatment of Patient with FloraStilbene CI
23-10-17 Res Nova Bio Appoints George Delgado to Scientific Advisory Board CI
23-09-29 Therapeutic Solutions International, Inc. Announces Paradigm Shifting Immunotherapy Product: Tolerogenic Neutrophils CI
23-09-18 Therapeutic Solutions International Appoints Navneet Boddu to Scientific Advisory Board CI
23-08-21 Therapeutic Solutions International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.06
10 years 0
Extreme 1.0E-6
0.17
Manager TitleAgeSince
Chief Executive Officer 68 2011-03-30
Chief Tech/Sci/R&D Officer 56 2019-09-02
Chief Tech/Sci/R&D Officer 61 2018-06-17
Director TitleAgeSince
Chairman 68 2012-01-02
Director/Board Member 51 2016-01-21
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/24 Free

Director

10,000,000 0.2047%
10/1/24 Free

Chief Executive Officer

55,555,555 1.1375%
7/11/24 Free

Chief Executive Officer

20,000,000 0.4356%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 7.05K
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.75%+78.12% 57.39B
+1.63%-1.61%+3.83%+36.89% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.41%+9.31%+58.85% 30.97B
+1.62%+5.23%+34.05%+28.83% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average +1.18%-0.12%+54.16%+128.26% 39.05B
Weighted average by Cap. +1.55%-0.41%+58.26%+137.27%

Financials

2022 2023
Net sales 207K 184K 172K 156K 295K 19.91M 297K 2.08M 808K 10.16M 776K 759K 32.67M 98.99K 88.31K 82.28K 74.87K 141K 9.53M 142K 994K 387K 4.87M 372K 364K 15.64M
Net income -3.68M -3.28M -3.06M -2.78M -5.24M -354M -5.28M -36.93M -14.37M -181M -13.81M -13.51M -581M -2.17M -1.94M -1.8M -1.64M -3.09M -209M -3.11M -21.79M -8.48M -107M -8.15M -7.97M -343M
Net Debt 1.06M 945K 881K 801K 1.51M 102M 1.52M 10.64M 4.14M 52.08M 3.98M 3.89M 167M 860K 767K 715K 651K 1.23M 82.85M 1.23M 8.64M 3.36M 42.28M 3.23M 3.16M 136M
Logo Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T Cell activity. It has developed an allogenic version of StemVacs and has filed patents to cover activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's natural killer (NK) cells. It has obtained exclusive rights to a patented adult stem cell for development of therapeutics in the area of chronic traumatic encephalopathy (CTE), TBI, and lung pathology.
Employees
3
Date Price Change Volume
26-10-05 US$0.000001 0.00% 2,000,000
26-10-01 US$0.000001 0.00% 8,000
  1. Stock Market
  2. Stocks
  3. TSOI Stock